Policy

Expert Discusses Chinese Biosimilar Business Prospects in the European Union

November 9th 2021

A consultant who specializes in helping Chinese biosimilar companies market their products in the European Union discusses the challenges and opportunities.

Dr Steven Yates Shares His Institutions's Policies on Nonmedical Switching and New Biosimilar Starts

November 7th 2021

Steven Yates, MD, discusses Intermountain Healthcare's policies surrounding switching patients from reference products to biosimilars.

AAM Jousts With Rebate Penalties for Generics and Biosimilars

November 5th 2021

By Tony Hagen

As House leaders sought to build support for the Build Back Better Act, the Association for Accessible Medicines (AAM) objected to drug price negotiations and proposed “rebate penalties.”

Prime Therapeutics Joins Express Scripts in Moving Semglee to Preferred Formulary Status

November 4th 2021

By Tony Hagen

Prime Therapeutics said that by putting Semglee (insulin glargine) on formulary, along with other biosimilars, it could achieve savings of $41 million or more per year.

IGBA Describes Competitive Economics of Biosimilars Industry

November 4th 2021

By Tony Hagen

Kicking off Global Biosimilars Week, the International Generic and Biosimilar Medicines Association (IGBA) released a blueprint detailing hurdles and opportunities for industry progress.

Pfizer to Seek Interchangeable Status for Abrilada Biosimilar

November 3rd 2021

By Tony Hagen

Pfizer reports on biosimilar revenues and says its switching studies for Abrilada, an adalimumab biosimilar, support interchangeable status.

Fresenius Kabi USA Executive Discusses Pegfilgrastim Biosimilar Prospects

November 2nd 2021

Ali Ahmed, senior vice president of biosimilars for Fresenius Kabi USA discusses FDA review of the company’s Stimufend pegfilgrastim biosimilar candidate and the marketing of this product.

AmerisourceBergen/Xcenda Policy Experts Discuss Biosimilar Strategy

October 31st 2021

Two AmerisourceBergen/Xcenda policy experts discuss the coming wave of pharmacy benefit biosimilars, formulary decisions, pricing transparency, and the Biden Administration’s push for lower-cost biologics.

Biosimilar Briefs: When to Switch to Biosimilars and More

October 30th 2021

An Emory pharmacy expert talks about the timing of switching to biosimliars, the Biosimilars Forum recommends biosimilars incentives, and Samsung Bioepis reaches a milestone.

An Interchangeable Biosimilars vs Authorized Biologics Battle May Be Looming

October 27th 2021

By Tony Hagen

Competitors in the field of adalimumab and insulin products may soon include “authorized biologics” in addition to biosimilars and interchangeable biosimilars, a pharmacy expert explains at the Academy of Managed Care Pharmacy Nexus 2021 meeting.